<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.102028</article-id><article-id pub-id-type="publisher-id">TCM-40938</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210200000_58726286.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于网络药理学和生物信息学探索逍遥散和柴胡疏肝散“同病异治”抑郁症的作用机制
  Study on Mechanism of Xiaoyao Powder and Chaihu Shugan Powder for Treating Depression in “the Same Disease with Different Treatments” Based on Network Pharmacology and Bioinformatics
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>文雯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>木</surname><given-names>本荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>钟</surname><given-names>馨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>志航</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>文萱</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卢</surname><given-names>长青</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>梁</surname><given-names>小清</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>冬梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>国</surname><given-names>锦琳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>成都中医药大学，四川 成都</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>02</month><year>2021</year></pub-date><volume>10</volume><issue>02</issue><fpage>200</fpage><lpage>215</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：使用网络药理学和生物信息学对在线数据库相关药材和疾病的数据进行挖掘并应用计算机工具探索逍遥散和柴胡疏肝散两个中药方剂“同病异治”抑郁症的活性成分和作用机制。方法：从TCMID、TCMSP、BATMAN-TCM 3个数据库中获取逍遥散和柴胡疏肝散两个药方组分、活性成分及其对应药物靶点信息。基于PharmGKB、DrugBank、OMIM、TTD、GeneCards五个疾病数据库结合NCBI-GEO生物芯片筛选抑郁症疾病靶点，比较药物靶点与疾病靶点的相关性。利用String在线分析工具和Cytoscape3.8.0对药物活性成分–疾病靶点进行可视化作图，采用拓扑分析、模块分析、GO富集分析和KEGG通路分析探索逍遥散和柴胡疏肝散“同病异治”抑郁症的关键基因与潜在靶点及作用通路。结果：逍遥散的活性成分有75个、对应的基因靶点有1960个，柴胡舒肝散的活性成分、对应的基因靶点有138个、1548个；逍遥散、柴胡疏肝散共有靶点就只有265个，为潜在抗抑郁靶点。经过网络分析以及拓扑和模块分析，得到MAPK14、NOS3、TOP2A、PTGS1、PTGS2、NCOA2、PTPN1、GABRA1、ESR2、AR、HSP90-1、PRSS1这12个基因靶点都可被认为是两个方剂共同抗抑郁的潜在靶点；逍遥散特有抗抑郁靶点有：GLUL、CREB1、GAD1、SLC6A1、GAD2、DAO、ADCY5、PPP1R1B、CRHR1、SLC1A2；柴胡疏肝散特有抗抑郁靶点是ALB。逍遥散和柴胡疏肝散作用抑郁症通路主要集中在癌症相关转录失调通路，钙信号通路，MAPK信号通路，调节干细胞多能性的信号通路；逍遥散特有抗抑郁通路主要集中在丙氨酸、天冬氨酸和谷氨酸代谢，GABA能突触，谷氨酸能突触等通路上。结论：柴胡疏肝散逍遥散和柴胡疏肝散能够通过相同靶点作用于抑郁症，也可以通过各自特有的靶点作用于抑郁症，从而有效治疗抑郁症，通过可视化和数据分析成分–靶点–疾病的相关性来阐释“同病异治”的科学内涵。 Objective: Using network pharmacology, bioinformatics and computer tools to mine the data of related medicinal materials and diseases in the online database, and to explore the active components and mechanism of Xiaoyao Powder and Chaihu Shugan Powder in the treatment of depression with the same disease with different treatments. Method: Through the TCMID, TCMSP, BATMAN-TCM to get compositions, active ingredients and the corresponding drug targets information of Xiaoyao Powder and Chaihu Shugan Powder. Five disease databases, PharmGKB, Drug Bank, OMIM, TTD, and Gene Cards, were combined with NCBI-GEO biochip to screen disease targets for depression, the correlation between drug targets and disease targets was compared. This paper used String online analysis tools and Cytoscape 3.8.0 to visualize the active ingredients of drugs-disease targets, used topological analysis, module analysis, GO enrichment analysis and KEGG pathway analysis to explore the key genes and potential targets and pathways of depression in Xiaoyao Powder and Chaihu Shugan Powder in “the same disease with different treatments. Results: There were 75 active ingredients and 1960 gene targets of Xiaoyao Powder, 138 active ingredients and 1548 gene targets of Chaihu Shugan Powder. There were 265 targets of Xiaoyao Powder and Chaihu Shugan Powder, which were potential antidepressant targets. Through network analysis, topology and module analysis, MAPK14, NOS3, TOP2A, PTGS1, PTGS2, NCOA2, PTPN1, GABRA1, ESR2, AR, HSP90-1, and PRSS1 were found to be potential anti-depression targets of the two prescriptions. The specific antidepres-sant targets of Xiaoyao Powder were GLUL, CREB1, GAD1, SLC6A1, GAD2, DAO, ADCY5, PPP1R1B, CRHR1, SLC1A2; the specific antidepressant target of Chaihu Shugan Powder was ALB. Xiaoyao Powder and Chaihu Shugan Powder mainly focused on cancer-related transcription disorders, calcium signaling pathways, MAPK signaling pathways, and signaling pathways regulating pluripotency of stem cells. The specific antidepressant pathways of Xiaoyao Powder mainly focused on the metabolism of alanine, aspartate and glutamate, GABAergic and glutamatergicsynapses. Conclusion: Xiaoyao Powder and Chaihu Shugan Powder can effectively treat depression through the same target action on depression, or through their own specific target actions on depression. The scientific connotation of “treating the same disease differently” is explained through the correlation between visualization and data analysis components-targets-diseases. 
   
   
    
  
 
</p></abstract><kwd-group><kwd>逍遥散，柴胡疏肝散，抑郁症，网络药理学，生物信息学，同病异治, Xiaoyao Powder</kwd><kwd> Chaihu Shugan Powder</kwd><kwd> Depression</kwd><kwd> Network Pharmacology</kwd><kwd> Bioinformatics</kwd><kwd> The Same Disease with Different Treatments</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：使用网络药理学和生物信息学对在线数据库相关药材和疾病的数据进行挖掘并应用计算机工具探索逍遥散和柴胡疏肝散两个中药方剂“同病异治”抑郁症的活性成分和作用机制。方法：从TCMID、TCMSP、BATMAN-TCM 3个数据库中获取逍遥散和柴胡疏肝散两个药方组分、活性成分及其对应药物靶点信息。基于PharmGKB、DrugBank、OMIM、TTD、GeneCards五个疾病数据库结合NCBI-GEO生物芯片筛选抑郁症疾病靶点，比较药物靶点与疾病靶点的相关性。利用String在线分析工具和Cytoscape3.8.0对药物活性成分–疾病靶点进行可视化作图，采用拓扑分析、模块分析、GO富集分析和KEGG通路分析探索逍遥散和柴胡疏肝散“同病异治”抑郁症的关键基因与潜在靶点及作用通路。结果：逍遥散的活性成分有75个、对应的基因靶点有1960个，柴胡舒肝散的活性成分、对应的基因靶点有138个、1548个；逍遥散、柴胡疏肝散共有靶点就只有265个，为潜在抗抑郁靶点。经过网络分析以及拓扑和模块分析，得到MAPK14、NOS3、TOP2A、PTGS1、PTGS2、NCOA2、PTPN1、GABRA1、ESR2、AR、HSP90-1、PRSS1这12个基因靶点都可被认为是两个方剂共同抗抑郁的潜在靶点；逍遥散特有抗抑郁靶点有：GLUL、CREB1、GAD1、SLC6A1、GAD2、DAO、ADCY5、PPP1R1B、CRHR1、SLC1A2；柴胡疏肝散特有抗抑郁靶点是ALB。逍遥散和柴胡疏肝散作用抑郁症通路主要集中在癌症相关转录失调通路，钙信号通路，MAPK信号通路，调节干细胞多能性的信号通路；逍遥散特有抗抑郁通路主要集中在丙氨酸、天冬氨酸和谷氨酸代谢，GABA能突触，谷氨酸能突触等通路上。结论：柴胡疏肝散逍遥散和柴胡疏肝散能够通过相同靶点作用于抑郁症，也可以通过各自特有的靶点作用于抑郁症，从而有效治疗抑郁症，通过可视化和数据分析成分–靶点–疾病的相关性来阐释“同病异治”的科学内涵。</p></sec><sec id="s2"><title>关键词</title><p>逍遥散，柴胡疏肝散，抑郁症，网络药理学，生物信息学，同病异治</p></sec><sec id="s3"><title>Study on Mechanism of Xiaoyao Powder and Chaihu Shugan Powder for Treating Depression in “the Same Disease with Different Treatments” Based on Network Pharmacology and Bioinformatics</title><p>Wenwen Liu<sup>*</sup>, Benrong Mu<sup>*</sup>, Xin Zhong, Zhihang Huang, Wenxuan Liu, Changqing Lu, Xiaoqing Liang, Dongmei Wang<sup>#</sup>, Jinlin Guo<sup>#</sup></p><p>Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan</p><p><img src="//html.hanspub.org/file/10-2270661x5_hanspub.png" /></p><p>Received: Feb. 12<sup>th</sup>, 2021; accepted: Mar. 8<sup>th</sup>, 2021; published: Mar. 15<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/10-2270661x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: Using network pharmacology, bioinformatics and computer tools to mine the data of related medicinal materials and diseases in the online database, and to explore the active components and mechanism of Xiaoyao Powder and Chaihu Shugan Powder in the treatment of depression with the same disease with different treatments. Method: Through the TCMID, TCMSP, BATMAN-TCM to get compositions, active ingredients and the corresponding drug targets information of Xiaoyao Powder and Chaihu Shugan Powder. Five disease databases, PharmGKB, Drug Bank, OMIM, TTD, and Gene Cards, were combined with NCBI-GEO biochip to screen disease targets for depression, the correlation between drug targets and disease targets was compared. This paper used String online analysis tools and Cytoscape 3.8.0 to visualize the active ingredients of drugs-disease targets, used topological analysis, module analysis, GO enrichment analysis and KEGG pathway analysis to explore the key genes and potential targets and pathways of depression in Xiaoyao Powder and Chaihu Shugan Powder in “the same disease with different treatments. Results: There were 75 active ingredients and 1960 gene targets of Xiaoyao Powder, 138 active ingredients and 1548 gene targets of Chaihu Shugan Powder. There were 265 targets of Xiaoyao Powder and Chaihu Shugan Powder, which were potential antidepressant targets. Through network analysis, topology and module analysis, MAPK14, NOS3, TOP2A, PTGS1, PTGS2, NCOA2, PTPN1, GABRA1, ESR2, AR, HSP90-1, and PRSS1 were found to be potential anti-depression targets of the two prescriptions. The specific antidepressant targets of Xiaoyao Powder were GLUL, CREB1, GAD1, SLC6A1, GAD2, DAO, ADCY5, PPP1R1B, CRHR1, SLC1A2; the specific antidepressant target of Chaihu Shugan Powder was ALB. Xiaoyao Powder and Chaihu Shugan Powder mainly focused on cancer-related transcription disorders, calcium signaling pathways, MAPK signaling pathways, and signaling pathways regulating pluripotency of stem cells. The specific antidepressant pathways of Xiaoyao Powder mainly focused on the metabolism of alanine, aspartate and glutamate, GABAergic and glutamatergicsynapses. Conclusion: Xiaoyao Powder and Chaihu Shugan Powder can effectively treat depression through the same target action on depression, or through their own specific target actions on depression. The scientific connotation of “treating the same disease differently” is explained through the correlation between visualization and data analysis components-targets-diseases.</p><p>Keywords:Xiaoyao Powder, Chaihu Shugan Powder, Depression, Network Pharmacology, Bioinformatics, The Same Disease with Different Treatments</p><disp-formula id="hanspub.40938-formula1"><graphic xlink:href="//html.hanspub.org/file/10-2270661x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-2270661x8_hanspub.png" /> <img src="//html.hanspub.org/file/10-2270661x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>抑郁症(Depression)是一种精神疾病，常表现为持续两周及以上的心绪低落、情绪不宁、易怒喜哭等症状，属于情感性心境障碍 [<xref ref-type="bibr" rid="hanspub.40938-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40938-ref2">2</xref>]。近年来，抑郁症的发展呈现年轻化和增长快两大趋势，轻度抑郁症可以影响患者的生活和人际交往，重度抑郁症患者会自残甚至自杀，严重危害了人类生活与健康 [<xref ref-type="bibr" rid="hanspub.40938-ref3">3</xref>]。目前西医治疗抑郁症以应用抗抑郁药物为主辅以心理干预，包括单胺氧化酶抑制剂、三环类药物、选择性5-羟色胺(5-HT)再摄取抑制剂等抗抑郁药物。其药效作用时间短，长期服用会导致不良反应，只能达到控制病情的效果，无法根治疾病 [<xref ref-type="bibr" rid="hanspub.40938-ref4">4</xref>]。随着中医药治疗疾病的崛起，国内外许多研究探索了中药治疗抑郁症的作用机制，发现并验证了许多可以治疗抑郁症的经典中药方剂。抑郁症在中医学上属于郁症范畴，其基本病机是肝失疏泄、脾失健运、脏腑阴阳气血失调，公认抑郁症的发病与肝的关系最为紧密。因此，目前已被证实的以疏肝解郁、理气开郁为原则有效治疗抑郁症的主要有柴胡疏肝散 [<xref ref-type="bibr" rid="hanspub.40938-ref5">5</xref>]、半夏厚朴汤 [<xref ref-type="bibr" rid="hanspub.40938-ref6">6</xref>]、越鞠丸 [<xref ref-type="bibr" rid="hanspub.40938-ref7">7</xref>]、逍遥散 [<xref ref-type="bibr" rid="hanspub.40938-ref8">8</xref>]、开心散 [<xref ref-type="bibr" rid="hanspub.40938-ref9">9</xref>]、四逆散 [<xref ref-type="bibr" rid="hanspub.40938-ref10">10</xref>]、柴桂温胆定志汤 [<xref ref-type="bibr" rid="hanspub.40938-ref11">11</xref>] 等中药药方。其中，研究大多为探索单个方剂对抑郁症的作用机制。然而，逍遥散和柴胡疏肝散两药方对于抑郁症“同病异治”的作用机制及有效活性成分尚未明确，有待进一步研究。</p><p>“同病异治”是指根据个人差异和病情严重程度采用不同的方剂治疗同一种疾病的一种治疗方法 [<xref ref-type="bibr" rid="hanspub.40938-ref12">12</xref>]。这符合中医学辨证施治的原则，同病异治的作用基础可能是两种方剂具有相同或相似的靶点，该靶点也可作用于疾病达到治疗“同病”的效果；也可能是两种方剂具有特有的靶点，该靶点亦可作用于疾病达到“异治”的效果。</p><p>网络药理学和生物信息学两者都是新兴的挖掘数据库信息的应用学科。网络药理学研究疾病作用机制的特点为多成分多靶点系统地进行网络分析，广泛应用于中药与疾病相关性的探索研究，已成为探索中药潜在机制常用的方法 [<xref ref-type="bibr" rid="hanspub.40938-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40938-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40938-ref15">15</xref>]。生物信息学运用计算机多种算法及统计学方法对生物数据信息进行分析，利用数据处理挖掘更多隐含的生物学意义 [<xref ref-type="bibr" rid="hanspub.40938-ref16">16</xref>]。</p><p>本研究通过对逍遥散和柴胡疏肝散活性成分和靶点的网络药理学和生物信息学数据挖掘，将药物靶点作为桥梁，把药材活性成分以及药物靶点和疾病靶点联系起来分析其相关性，通过靶点的通路分析阐释逍遥散和柴胡疏肝散“同病异治”抑郁症的科学内涵。</p></sec><sec id="s6"><title>2. 材料和方法</title><sec id="s6_1"><title>2.1. 逍遥散和柴胡疏肝散活性成分和靶点筛选</title><p>在TCMID (http://119.3.41.228:8000/tcmid/)中搜索关键词：逍遥散、柴胡疏肝散。得到逍遥散组分为柴胡、当归、白术、白芍、茯苓、薄荷、生姜、炙甘草八味中药材，柴胡疏肝散组分为柴胡、陈皮、川芎、香附、枳壳、白芍、甘草七位中药材。使用TCMSP (https://tcmspw.com/tcmsp.php)和BATMAN-TCM (http://bionet.ncpsb.org.cn/batman-tcm/)在线分析平台检索逍遥散和柴胡疏肝散两个药方中各自组分的活性成分和靶点。在TCMSP中筛选两药方各单味药口服生物利用度OB (oral bioavailability) ≥ 30%和类药性DL (drug likeness) ≥ 0.18的有效活性成分，在BATMAN-TCM (http://bionet.ncpsb.org.cn/batman-tcm/)数据库中检索单味药且仅保留评分 ≥ 20分的潜在靶点，收集整理出对应的蛋白质靶点和基因靶点。</p></sec><sec id="s6_2"><title>2.2. 潜在蛋白质靶点转化为基因靶点</title><p>在TCMSP中收集整理的药物靶点都是蛋白质靶点，需要进入Uniport数据库，利用UniprotKB将蛋白质靶点转化为基因靶点，筛选条件为：Reviewed (Swiss-Prot)并选择Popular organisms: Human。而BATMAN-TCM中搜索单味药的靶点得到的是Gene Symbol，即基因靶点。收集整理两大数据库的靶点，去除重复靶点，得到各单味药材的基因靶点。使用Venny 2.1.0在线画图软件绘制维恩图，得到两种药方的共有和特有靶点的具体信息。</p></sec><sec id="s6_3"><title>2.3. 抑郁症GEO数据集差异基因的筛选</title><p>进入美国国立生物中心基因表达综合数据库(NCBI-GEO, https://www.ncbi.nlm.nih.gov/)，下载GSE94988芯片数据。该数据集包含9个样本，其中6例为慢性非预测性轻度应激诱导的抑郁症，3例为控制对照样本组，分组后进行GEO2R分析后下载全部基因资料，除去没有匹配到基因的探针，筛选P &lt; 0.05，log<sub>2</sub>FC &gt; 2或log<sub>2</sub>FC &lt; −2得到抑郁症患病组与正常组的差异基因，并使用R语言对数据集基因绘制火山图，对差异基因绘制热图，进行可视化分析。</p></sec><sec id="s6_4"><title>2.4. 疾病数据库中抑郁症靶点的筛选</title><p>PharmGKB (https://www.pharmgkb.org/), DrugBank (https://go.drugbank.com/), OMIM (https://omim.org/), TTD (http://db.idrblab.net/ttd/), Gene Cards (https://www.genecards.org/)五个疾病数据库中以“depression”为关键词检索收集整理得到抑郁症相关靶点。</p></sec><sec id="s6_5"><title>2.5. 蛋白质互作网络(Protein-Protein Interaction Networks, PPI)的构建</title><p>采用String11.0 (https://www.string-db.org/)在线工具，在Multiple proteins功能导入逍遥散–柴胡疏肝散-抑郁症共有靶点，选择Organism: Homo sapiens，构建逍遥散–柴胡疏肝散–抑郁症共有靶点PPI。其中参数设置：最低互作分值默认为0.4，勾选隐藏网络中断开的节点。根据Venn图获得逍遥散、柴胡疏肝散特有靶点，分别构建逍遥散特有靶点–抑郁症靶点PPI以及柴胡疏肝散特有靶点–抑郁症靶点PPI。</p></sec><sec id="s6_6"><title>2.6. 药物活性成分–疾病靶点互作网络的构建</title><p>使用Cytoscape3.8.0软件分别构建逍遥散活性成分–靶点互作网络、柴胡舒肝散活性成分–靶点互作网络以及两个药方共有或特有活性成分–抑郁症作用靶点网络。采用拓扑和模块分析可获得逍遥散和柴胡疏肝散靶点与抑郁症的关系。</p></sec><sec id="s6_7"><title>2.7. 潜在抗抑郁共有靶点的GO和KEGG分析</title><p>逍遥散–柴胡疏肝散共有靶点再与抑郁症靶点求交集得到的两种药方——疾病共有靶点将成为逍遥散和柴胡疏肝散“同病异治”抑郁症的潜在抗抑郁靶点。将三者共有靶点基因列表导入DAVID6.8 (https://david.ncifcrf.gov/)在线分析平台得到生物过程(Biological Process)、细胞组成(Cellular Component)、分子功能(Molecular Function)以及KEGG通路分析列表。利用R语言ggplot2包绘制GO富集分析和KEGG通路分析气泡图。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 逍遥散和柴胡疏肝散活性成分和靶点筛选</title><p>通过TCMSP、BATMAN-TCM数据库检索，结合文献查找逍遥散和柴胡疏肝散各自的组分、单味药材的活性成分及对应靶点，删去重复值。结果显示，逍遥散的活性成分有75个、对应的基因靶点有1960个，柴胡舒肝散的活性成分、对应的基因靶点有138个、1548个。两个药方中共有的单味药有柴胡和白芍。两个不同的药方如果有相同的成分和共有靶点与疾病相作用，即可达到“同病异治”的效果，即治疗同一种疾病。同时药方因为组分不同，其特有靶点也可能是抑郁症的潜在作用靶点。</p></sec><sec id="s7_2"><title>3.2. 抑郁症相关靶点</title><p>将疾病数据库所得到的抑郁症相关靶点与GEO数据库GSE94988基因芯片数据及分析得出的差异基因合并，得到需要分析的总的抑郁症靶点集合，去除重复基因靶点。在NCBI-GEO中搜索GSE94988经过GEO2R分析下载原始数据，然后经P &lt; 0.05，log<sub>2</sub>FC &lt; −2或log<sub>2</sub>FC &gt; 2筛选，排除无对应基因名的基因，得到128个差异基因，并绘制火山图。再通过PharmGKB，DrugBank，OMIM，TTD，GeneCards五个疾病数据库的关键词检索，去除重复值，收集整合出抑郁症靶点共1538个。使用R语言软件绘制火山图(见图1)，其中log<sub>2</sub>FC &gt; 2且P值&lt;0.05的基因为抑郁症患者体内表达上调的基因，图中呈现为红色，共62个；log<sub>2</sub>FC &lt; −2且P值&lt;0.05的基因呈现绿色，共66个；P值&gt;0.05，无显著性差异，即无统计学意义的基因呈现为黑点。将筛选得到的差异基因绘制热图(见图2)。</p><p>图1. GSE94988基因芯片数据集差异基因火山图</p><p>图2. 差异基因热图</p></sec><sec id="s7_3"><title>3.3. 逍遥散–柴胡疏肝散–抑郁症共有靶点</title><p>将逍遥散和柴胡疏肝散基因靶点数据导入到Calculateand draw custom Venn diagrams (http://bioinformatics.psb.ugent.be/webtools/Venn/)在线统计分析平台，得到逍遥散—柴胡疏肝散共有靶点和特有靶点。</p><p>使用Venny 2.1. (https://bioinfogp.cnb.csic.es/tools/venny/)在线画图软件绘制逍遥散–柴胡疏肝散–抑郁症共有靶点的维恩图，见图3，得到交集265个，说明药物共有活性成分与抑郁症有关的靶点有265个，即两个药方治疗抑郁症的潜在靶点，整理得到基因靶点具体信息。</p><p>图3. 逍遥散–柴胡疏肝散–抑郁症共同靶点</p></sec><sec id="s7_4"><title>3.4. 药物活性成分–疾病靶点互作网络及拓扑和模块分析</title><p>运用Cytoscape3.8.0软件中的Tools-Network Analyzer来进行拓扑分析，通过大小、颜色、网络边数密集程度差异可视化评价逍遥散和柴胡疏肝散的潜在抗抑郁靶点。在Cytoscape中分别导入逍遥散、柴胡疏肝散活性成分及靶点(见图4及图5)；两者共有或特有的活性成分及靶点作图(见图6)。根据Degree大小分别得到度值前十的拓扑分析，逍遥散潜在靶点的拓扑分析(见表1)；柴胡疏肝散潜在靶点拓扑分析(见表2)；同病异治潜在靶点的拓扑分析(见表4)。表3为逍遥散和柴胡疏肝散特有和共有活性成分相关信息。在拓扑分析中，一个节点的介度(Degree)越大就提示着这个节点的度中心性越高，该节点即靶点，在网络中就越重要，该是在网络分析中反应节点重要性的最直接指标。</p><p>图4. 逍遥散活性成分–靶点蛋白质互作网络</p><p>图5. 柴胡疏肝散活性成分–靶点蛋白质互作网络</p><p>图6. 逍遥散、柴胡舒肝散共有或特有化学成分–抑郁症靶点互作网络</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Topological analysis of potential targets of Xiaoyao powder (top 10</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >序号</th><th align="center" valign="middle" >基因靶点</th><th align="center" valign="middle" >平均最短路径</th><th align="center" valign="middle" >介度 (Degree)</th><th align="center" valign="middle" >中介中心性(Betweenness)</th><th align="center" valign="middle" >中心接近度(Closeness)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >PTGS2</td><td align="center" valign="middle" >1.987096774</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >0.089986305</td><td align="center" valign="middle" >0.503246753</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >NCOA2</td><td align="center" valign="middle" >2.225806452</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >0.054429305</td><td align="center" valign="middle" >0.449275362</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >PTGS1</td><td align="center" valign="middle" >2.032258065</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0.06686081</td><td align="center" valign="middle" >0.492063492</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >HSP90-1</td><td align="center" valign="middle" >2.264516129</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >0.02572542</td><td align="center" valign="middle" >0.441595442</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >PGR</td><td align="center" valign="middle" >2.95483871</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >0.030302125</td><td align="center" valign="middle" >0.338427948</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >PRKACA</td><td align="center" valign="middle" >2.238709677</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >0.02453043</td><td align="center" valign="middle" >0.446685879</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >7</th><th align="center" valign="middle" >GABRA1</th><th align="center" valign="middle" >2.438709677</th><th align="center" valign="middle" >11</th><th align="center" valign="middle" >0.015266549</th><th align="center" valign="middle" >0.41005291</th></tr></thead><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >PRSS1</td><td align="center" valign="middle" >2.522580645</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.0102497</td><td align="center" valign="middle" >0.396419437</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >PIK3CG</td><td align="center" valign="middle" >2.296774194</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.019280335</td><td align="center" valign="middle" >0.435393258</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >AR</td><td align="center" valign="middle" >2.387096774</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.02106464</td><td align="center" valign="middle" >0.418918919</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 逍遥散潜在靶点(介度前十)的拓扑分析</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Topological analysis of potential targets of ChaihuShugan powder (top 10</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >序号</th><th align="center" valign="middle" >基因靶点</th><th align="center" valign="middle" >平均最短路径</th><th align="center" valign="middle" >介度 (Degree)</th><th align="center" valign="middle" >中介中心性(Betweenness)</th><th align="center" valign="middle" >中心接近度(Closeness)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >PTGS2</td><td align="center" valign="middle" >1.7825</td><td align="center" valign="middle" >116</td><td align="center" valign="middle" >0.10397894</td><td align="center" valign="middle" >0.56100982</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >HSP90-1</td><td align="center" valign="middle" >1.9775</td><td align="center" valign="middle" >88</td><td align="center" valign="middle" >0.05435557</td><td align="center" valign="middle" >0.505689</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >CALM</td><td align="center" valign="middle" >2.5725</td><td align="center" valign="middle" >86</td><td align="center" valign="middle" >0.01755302</td><td align="center" valign="middle" >0.38872692</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >ESR1</td><td align="center" valign="middle" >2.6375</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >0.01884549</td><td align="center" valign="middle" >0.37914692</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >PPARG</td><td align="center" valign="middle" >2.0825</td><td align="center" valign="middle" >82</td><td align="center" valign="middle" >0.03461861</td><td align="center" valign="middle" >0.48019208</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >AR</td><td align="center" valign="middle" >2.1575</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >0.02834164</td><td align="center" valign="middle" >0.46349942</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >NOS2</td><td align="center" valign="middle" >2.6425</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >0.01162611</td><td align="center" valign="middle" >0.37842952</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >NCOA2</td><td align="center" valign="middle" >2.1725</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >0.04955221</td><td align="center" valign="middle" >0.46029919</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >PTGS1</td><td align="center" valign="middle" >2.0425</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >0.04661656</td><td align="center" valign="middle" >0.48959608</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >PRSS1</td><td align="center" valign="middle" >2.2225</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >0.02513472</td><td align="center" valign="middle" >0.44994376</td></tr></tbody></table></table-wrap><p>表2. 柴胡疏肝散潜在靶点(介度前十)的拓扑分析</p><table-wrap-group id="3"><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Unique and common active ingredients of Xiaoyao powder and ChaihuShugan powde</title></caption><table-wrap id="3_1"><table><tbody><thead><tr><th align="center" valign="middle" >Molecule ID</th><th align="center" valign="middle" >化学成分</th><th align="center" valign="middle" >Type</th></tr></thead><tr><td align="center" valign="middle" >MOL004624</td><td align="center" valign="middle" >Longikaurin A</td><td align="center" valign="middle" >A</td></tr><tr><td align="center" valign="middle" >MOL004653</td><td align="center" valign="middle" >(+)-Anomalin</td><td align="center" valign="middle" >A</td></tr><tr><td align="center" valign="middle" >MOL000490</td><td align="center" valign="middle" >petunidin</td><td align="center" valign="middle" >A</td></tr><tr><td align="center" valign="middle" >MOL004598</td><td align="center" valign="middle" >3,5,6,7-tetramethoxy-2-(3,4,5-trimethoxyphenyl)chromone</td><td align="center" valign="middle" >A</td></tr><tr><td align="center" valign="middle" >MOL004609</td><td align="center" valign="middle" >Areapillin</td><td align="center" valign="middle" >A</td></tr><tr><td align="center" valign="middle" >MOL000492</td><td align="center" valign="middle" >(+)-catechin</td><td align="center" valign="middle" >A</td></tr><tr><td align="center" valign="middle" >MOL001689</td><td align="center" valign="middle" >acacetin</td><td align="center" valign="middle" >A</td></tr><tr><td align="center" valign="middle" >MOL000471</td><td align="center" valign="middle" >aloe-emodin</td><td align="center" valign="middle" >A</td></tr><tr><td align="center" valign="middle" >MOL001645</td><td align="center" valign="middle" >Linoleyl acetate</td><td align="center" valign="middle" >B</td></tr><tr><td align="center" valign="middle" >MOL005815</td><td align="center" valign="middle" >Citromitin</td><td align="center" valign="middle" >B</td></tr><tr><td align="center" valign="middle" >MOL002157</td><td align="center" valign="middle" >wallichilide</td><td align="center" valign="middle" >B</td></tr><tr><td align="center" valign="middle" >MOL004071</td><td align="center" valign="middle" >Hyndarin</td><td align="center" valign="middle" >B</td></tr><tr><td align="center" valign="middle" >MOL000392</td><td align="center" valign="middle" >formononetin</td><td align="center" valign="middle" >B</td></tr><tr><td align="center" valign="middle" >MOL000449</td><td align="center" valign="middle" >Stigmasterol</td><td align="center" valign="middle" >C</td></tr><tr><td align="center" valign="middle" >MOL000354</td><td align="center" valign="middle" >isorhamnetin</td><td align="center" valign="middle" >C</td></tr></tbody></table></table-wrap><table-wrap id="3_2"><table><tbody><thead><tr><th align="center" valign="middle" >MOL000422</th><th align="center" valign="middle" >kaempferol</th><th align="center" valign="middle" >C</th></tr></thead><tr><td align="center" valign="middle" >MOL000098</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >C</td></tr><tr><td align="center" valign="middle" >MOL004328</td><td align="center" valign="middle" >naringenin</td><td align="center" valign="middle" >C</td></tr><tr><td align="center" valign="middle" >MOL000358</td><td align="center" valign="middle" >beta-sitosterol</td><td align="center" valign="middle" >C</td></tr><tr><td align="center" valign="middle" >MOL000006</td><td align="center" valign="middle" >luteolin</td><td align="center" valign="middle" >C</td></tr><tr><td align="center" valign="middle" >MOL001924</td><td align="center" valign="middle" >paeoniflorin</td><td align="center" valign="middle" >C</td></tr><tr><td align="center" valign="middle" >MOL002776</td><td align="center" valign="middle" >Baicalin</td><td align="center" valign="middle" >C</td></tr></tbody></table></table-wrap></table-wrap-group><p>表3. 逍遥散和柴胡疏肝散特有和共有活性成分</p><p>A：TCMSP数据库中逍遥散特有活性成分Molecule ID；B：TCMSP数据库中柴胡疏肝散特有活性成分Molecule ID；C：TCMSP数据库中逍遥散–柴胡疏肝散共有活性成分Molecule ID。</p><p>A: Molecule IDs of the unique active ingredients of Xiaoyao Powder in TCMSP database; B: Molecule IDs of the unique active ingredients of ChaihuShugan powder in TCMSP database; C: Molecule IDs of the common active ingredient of Xiaoyao Powder and ChaihuShugan powder in TCMSP database.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Topological analysis of potential targets for treatment of the same diseas</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >序号</th><th align="center" valign="middle" >基因靶点</th><th align="center" valign="middle" >平均最短路径</th><th align="center" valign="middle" >介度 (Degree)</th><th align="center" valign="middle" >中介中心性(Betweenness)</th><th align="center" valign="middle" >中心接近度(Closeness)</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >MAPK14</td><td align="center" valign="middle" >3.348484848</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.026941406</td><td align="center" valign="middle"  colspan="2"  >0.298642534</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >NOS3</td><td align="center" valign="middle" >3.106060606</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.036404751</td><td align="center" valign="middle"  colspan="2"  >0.32195122</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >TOP2A</td><td align="center" valign="middle" >3.106060606</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.045807392</td><td align="center" valign="middle"  colspan="2"  >0.32195122</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >PTGS1</td><td align="center" valign="middle" >3.5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.040746112</td><td align="center" valign="middle"  colspan="2"  >0.285714286</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >PTGS2</td><td align="center" valign="middle" >3.5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.040746112</td><td align="center" valign="middle"  colspan="2"  >0.285714286</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >NCOA2</td><td align="center" valign="middle" >3.651515152</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.037306</td><td align="center" valign="middle"  colspan="2"  >0.273858921</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >PTPN1</td><td align="center" valign="middle" >3.696969697</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.012528429</td><td align="center" valign="middle"  colspan="2"  >0.270491803</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >GABRA1</td><td align="center" valign="middle" >3.590909091</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.011088591</td><td align="center" valign="middle"  colspan="2"  >0.278481013</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >ESR2</td><td align="center" valign="middle" >3.590909091</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.011088591</td><td align="center" valign="middle"  colspan="2"  >0.278481013</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >AR</td><td align="center" valign="middle" >3.5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.005657166</td><td align="center" valign="middle"  colspan="2"  >0.285714286</td></tr></tbody></table></table-wrap><p>表4. 同病异治潜在靶点的拓扑分析</p><p>使用Cytoscape中Tools-Network Analyzer可以依托Degree值评价网络，通过数值比较更好地展现药材活性成分、靶点与抑郁症靶点的关系。Degree值越大，在图中显示出的形状越大，则该物质在网络中越重要。由于TCMSP数据库中不含有炙甘草这一单味药的化学成分和靶点，因此在使用Cytoscape绘制网络时采用了BATMAN-TCM中的炙甘草相关化学成分和靶点，进入TCMSP中通过搜索chemicalname找到对应Molecule ID，以方便可视化绘制PPI。</p><p>由网络图和表中的拓扑分析可得，度值前十的逍遥散抗抑郁的潜在靶点有：PTGS2、NCOA2、PTGS1、HSP90-1、PGR、PRKACA、GABRA1、PRSS1、PIK3CG、AR，(见表1)；柴胡疏肝散抗抑郁的潜在靶点有：PTGS2、HSP90-1、CALM、ESR1、PPARG、AR、NOS2、NCOA2、PTGS1、PRSS1，(见表2)；两者共同抗抑郁潜在靶点有MAPK14、NOS3、TOP2A、PTGS1、PTGS2、NCOA2、PTPN1、GABRA1、ESR2、AR (见表4)。综上，MAPK14、NOS3、TOP2A、PTGS1、PTGS2、NCOA2、PTPN1、GABRA1、ESR2、AR、HSP90-1、PRSS1这12个基因靶点都是两个方剂共同抗抑郁的潜在靶点。由图6可以得到逍遥散和柴胡疏肝散的共有活性成分MOL000422：山柰酚(kaempferol)和MOL000098：槲皮苷(quercetin)在网络图中因Degree值较高而展现出显著差异，这提示山柰酚和槲皮苷可以用以治疗抑郁症。</p></sec><sec id="s7_5"><title>3.5. 蛋白质互作网络(PPI)分析</title><p>PPI是由蛋白质通过彼此相互作用构成。它用于参加基因表达调控、信息转导等重要生命活动，通过PPI网络的分析能够了解蛋白质之间的功能关系。运用String11.0在线工具，分别导入两药–疾病共有靶点，以及两药特有靶点–抑郁症靶点。在两药-疾病共有靶点的互作网络中(如图7)，有265个节点，4564条边；在逍遥散特有靶点–抑郁症靶点互作网络中(如图8)，有65个节点，123条边；在柴胡疏肝</p><p>图7. 逍遥散–柴胡疏肝散–抑郁症共有靶点蛋白质相互作用网络</p><p>图8. 逍遥散特有靶点–抑郁症蛋白质互作网络</p><p>散特有靶点–抑郁症互作网络中(如图9)，有9个节点，5条边。在PPI中，节点代表靶点，边数可以直接反映蛋白质之间的相关性，即边越多的节点指示该节点在网络作用中起枢纽作用。</p><p>图9. 柴胡疏肝散特有靶点–抑郁症蛋白质互作网络</p><p>将String分析后的逍遥散和柴胡疏肝散特有靶点分别导入Cytoscape中，经过度值分析，得到逍遥散特有抗抑郁靶点中度值较大的有：GLUL、CREB1、GAD1、SLC6A1、GAD2、DAO、ADCY5、PPP1R1B、CRHR1、SLC1A2，柴胡疏肝散特有抗抑郁靶点中度值较大的有：ALB。</p><p>采用Cytoscape-ClusterViz进行模块分析，选择MCODE算法对两药–疾病共有靶点进行聚类分析 [<xref ref-type="bibr" rid="hanspub.40938-ref17">17</xref>]，设置默认值参数NodeScore Threshold = 0.2，K-Core Threshold = 4。K-Core是决定识别模块大小的参数，即获得的模块所对应的边应大于2。如表5所示，得到6个模块，每个模块的基因数目分别为43，34，38，24，7，17。将模块对应的基因列表导入DAVIID中进行KEGG通路分析，得到相关通路。发现不同模块间存在相同通路，如Prostate cancer, Basal cell carcinoma, Pathways in cancer, Estrogen signaling pathway, cAMP signaling pathway, Calcium signaling pathway等。</p><table-wrap-group id="5"><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Common targets module analysi</title></caption><table-wrap id="5_1"><table><tbody><thead><tr><th align="center" valign="middle" >Cluster</th><th align="center" valign="middle" >模块</th><th align="center" valign="middle" >Score</th><th align="center" valign="middle" >通路</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/10-2270661x19_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >36.476</td><td align="center" valign="middle" >Pathways in cancer, Transcriptional misregulation in cancer, Calcium signaling pathway, MAPK signalingpathway, Signaling pathways regulating pluripotencyof stemcells, Small cell lung cancer, Prostate cancer, HIF-1 signaling pathway, Amyotrophic lateral sclerosis (ALS), Endometrial cancer, Basal cell carcinoma, Non-small cell lung cancer</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/10-2270661x20_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >12.667</td><td align="center" valign="middle" >Dopaminergic synapse, Neuroactive ligand-receptor interaction, Tyrosine metabolism, Basal cell carcinoma, Serotonergic synapse, Cocaine addiction, cAMP signaling pathway, Phenylalanine metabolism, Signaling pathways regulating, cGMP-PKG signaling pathway, Alcoholism, Tryptophan metabolism, Endometrial cancer, Pathways in cancer, Hippo signaling pathway, Colorectal cancer, Amphetamine addiction, Prostate cancer, Focal adhesion, Rap1 signaling pathway, Estrogen signaling pathway, Melanogenesis, Thyroid hormone signaling pathway, HTLV-I infection, Sphingolipid signaling pathway, Histidine metabolism</td></tr></tbody></table></table-wrap><table-wrap id="5_2"><table><tbody><thead><tr><th align="center" valign="middle" >3</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/10-2270661x21_hanspub.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" >11.189</th><th align="center" valign="middle" >Nicotine addiction, Amphetamine addiction, Cocaine addiction, Glutamatergic synapse, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Alcoholism, Dopaminergic synapse, Amyotrophic lateral sclerosis (ALS) , Calcium signaling pathway, Long-term potentiation, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Long-term depression, Alzheimer’s disease, Serotonergic synapse, Central carbon metabolism in cancer, Pathways in cancer, ErbB signaling pathway</th></tr></thead><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/10-2270661x22_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >9.739</td><td align="center" valign="middle" >Neuroactive ligand-receptor interaction, Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Serotonergic synapse, Cholinergic synapse, cAMP signaling pathway, Vascular smooth muscle contraction, Adrenergic signaling in cardiomyocytes, Salivary secretion, Estrogen signaling pathway, Chagas disease (American trypanosomiasis), Amoebiasis, Glutamatergic synapse, Platelet activation, Oxytocin signaling pathway, cGMP-PKG signaling pathway</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/10-2270661x23_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >Neuroactive ligand-receptor interaction, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Serotonergic synapse, Cholinergic synapse, cAMP signaling pathway, Vascular smooth muscle contraction, Adrenergic signaling in cardiomyocytes, Salivary secretion, Estrogen signaling pathway, Chagas disease, Amoebiasis, Glutamatergic synapse, Platelet activation, Oxytocin signaling pathway, cGMP-PKG signaling pathway</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/10-2270661x24_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >6.375</td><td align="center" valign="middle" >Neuroactive ligand-receptor interaction, Morphineaddiction, Nicotine addiction, Retrogradeendocannabinoid signaling, Dopaminergic synapse, GABAergic synapse, Calcium signaling pathway, cAMP signaling pathway, Serotonergic synapse, Amphetamine addiction, Cocaine addiction, Glutamatergic synapse</td></tr></tbody></table></table-wrap></table-wrap-group><p>表5. 共有靶点模块分析</p></sec><sec id="s7_6"><title>3.6. 潜在靶点GO和KEGG分析</title><p>DAVID6.8 (https://david.ncifcrf.gov/)是一个生物信息学常用的数据库，用以给基因或蛋白列表提供系统的生物功能注释生物学信息。将共有靶点导入DAVID中，利用R Studio作BP、CC、MF、KEGG气泡图。根据气泡图中的气泡大小和颜色可以得到在该项目中的富集程度，即气泡大小代表该项目下的靶点数，而气泡颜色的变化代表-log10 (P Value)的变化，气泡越大，颜色越深，则该项目在此通路或位置上富集程度越大，有十分重要的作用。两种药方——疾病共有靶点将成为逍遥散和柴胡疏肝散“同病异治”抑郁症的潜在抗抑郁靶点。GO和KEGG分析显示，生物过程(BP)共有52条富集结果，细胞组成(CC) 12条、分子功能(MF) 19条以及KEGG通路6条。结果指示两种方剂共同抗抑郁的生物进程主要体现在调亡过程负调控(negative regulation of apoptotic process)，GTP酶活性的正调控(positive regulation of GTPase activity)，基因表达正调控(positive regulation of gene expression) (见图10)；细胞组成主要体现在细胞外(见图11)；分子功能则集中在血红素结合(heme binding)，血红素结合铁离子(iron ion binding)以及氧结合(oxygen binding) (见图12)；通路集中在癌症中的通路(pathway in cancer)，转录调控失调(transcriptional misregulation in cancer)，钙信号通路(calcium signaling pathway)，MAPK信号通路(MAPK signaling pathway)，调节干细胞多能性的信号通路(signaling pathway regulating pluripotency of stem cells) (见图13)。其中在前期我们的研究中 [<xref ref-type="bibr" rid="hanspub.40938-ref18">18</xref>]，发现钙信号通路与抑郁症发病有关的结论是切合的，这个通路也已经被多人证实与抑郁症有关 [<xref ref-type="bibr" rid="hanspub.40938-ref19">19</xref>]。本研究的结果提示可能抑郁症也与癌症和转录失调有关。同时将特有靶点导入DAVID中得到特有靶点的抗抑郁通路。逍遥散特有抗抑郁通路主要集中在丙氨酸、天冬氨酸和谷氨酸代谢(Alanine, aspartate and glutamate metabolism)，GABA能突触(GABAergic synapse)，谷氨酸能突触(glutamatergic synapse)等通路上。而柴胡疏肝散的特有抗抑郁靶点ALB即白蛋白，这也指示了白蛋白可能在正常和抑郁症患者中有差异。</p><p>图10. 共有靶点BP富集分析气泡图</p><p>图11. 共有靶点CC富集分析气泡</p><p>图12. 共有靶点MF富集分析气泡图</p><p>图13. 共有靶点KEGG通路分析气泡图</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>近年来，逍遥散和柴胡疏肝散分别作为疏肝解郁名方对治疗抑郁症的研究越来越热。关于逍遥散和柴胡疏肝散各自单独对于抑郁症的治疗，部分学者已有了预测，但其治疗抑郁症的真正作用机制还需要进一步探讨。有关抑郁症的发病机制研究有以下广泛认同的假说：炎症因子假说，单胺类神经递质假说，脑源性神经营养因子(BDNF)假说 [<xref ref-type="bibr" rid="hanspub.40938-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40938-ref20">20</xref>]。其中，单胺类神经递质假说研究最为深入。该假说中，多巴胺，5-羟色胺(5-HT)等神经递质水平在抑郁症患者终会明显降低，而在应用治疗后又会明显提高 [<xref ref-type="bibr" rid="hanspub.40938-ref21">21</xref>]。</p><p>逍遥散长期应用于治疗肝郁脾虚之症，且效果显著 [<xref ref-type="bibr" rid="hanspub.40938-ref22">22</xref>]。逍遥散的抗抑郁成分柴胡皂苷A、柴胡皂苷D、阿魏酸、芍药苷、甘草苷、白术内酯主要来源于柴胡、白术、当归、白芍、炙甘草5味药材 [<xref ref-type="bibr" rid="hanspub.40938-ref23">23</xref>]，其主要通过提高单胺类神经递质5-HT、BDNF含量、提高BDNF含量即提高神经元可塑性协同发挥抗抑郁作用 [<xref ref-type="bibr" rid="hanspub.40938-ref24">24</xref>]。有研究表明，抑郁症的发病与神经突触间隙内的5-HT浓度有关 [<xref ref-type="bibr" rid="hanspub.40938-ref25">25</xref>]，而5-HT是色氨酸(TRP)的代谢产物，因此，抑郁症的发病与色氨酸代谢有关 [<xref ref-type="bibr" rid="hanspub.40938-ref26">26</xref>]。在我们的研究结果中发现逍遥散特有抗抑郁通路主要集中在丙氨酸、天冬氨酸和谷氨酸代谢，GABA能突触，谷氨酸能突触等通路上，这也提示了抑郁症的发病可能与丙氨酸、天冬氨酸和谷氨酸代谢有关，有待进一步研究证实。柴胡疏肝散是疏肝解郁理气的常用方剂，为疏肝理气之代表方剂之一。药方中柴胡疏肝解郁，解表和里；川芎活血行气，止痛解郁；陈皮理气燥湿，通调气机；香附清郁解热，理气降噪；甘草养血柔肝，调和诸药 [<xref ref-type="bibr" rid="hanspub.40938-ref27">27</xref>]；枳壳疏肝理气、消痞除胀 [<xref ref-type="bibr" rid="hanspub.40938-ref28">28</xref>]；白芍养血敛阴，平抑肝阳 [<xref ref-type="bibr" rid="hanspub.40938-ref29">29</xref>]。其主要功能是解郁散结，调气疏肝，主治肝郁气滞所致的胁肋疼痛，或纳少腹胀等症。柴胡疏肝散在中国和其他远东国家已被临床用于治疗情绪疾病近四个世纪 [<xref ref-type="bibr" rid="hanspub.40938-ref30">30</xref>]。Yuan-yue Liu等研究发现柴胡疏肝散的靶基因涉及细胞生长、分化和凋亡过程、代谢过程、中枢神经系统调控、药物反应、突触调控等生物学过程 [<xref ref-type="bibr" rid="hanspub.40938-ref31">31</xref>]。有文献报道的抑郁症发病机制涉及神经递质和炎症调节等生物过程 [<xref ref-type="bibr" rid="hanspub.40938-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.40938-ref33">33</xref>] [<xref ref-type="bibr" rid="hanspub.40938-ref34">34</xref>]，这与柴胡疏肝散的靶基因相关联。在本次研究中，我们通过逍遥散和柴胡疏肝散的共有活性成分作用抑郁症靶点的网络图可以推测山柰酚(kaempferol)和槲皮苷(quercetin)可以用以治疗抑郁症。此外，本研究的结果提示可能抑郁症也与癌症和转录失调有关。两种方剂共同抗抑郁的生物进程主要体现在调亡过程负调控，GTP酶活性的正调控，基因表达正调控；逍遥散特有抗抑郁通路主要集中在丙氨酸、天冬氨酸和谷氨酸代谢，GABA能突触，谷氨酸能突触等通路上；柴胡疏肝散的特有抗抑郁靶点ALB即白蛋白，通过查阅资料，发现血清ALB、PA在抑郁症患者中呈低表达水平，与抑郁症患者汉密尔顿抑郁量表(HAMD)评分呈负相关 [<xref ref-type="bibr" rid="hanspub.40938-ref35">35</xref>]，证实了ALB表达与抑郁症发病相关联，也证实了本研究的科学性。</p><p>本次研究中，通过网络药理学和生物信息学分析数据得到MAPK14、NOS3、TOP2A、PTGS1、PTGS2、NCOA2、PTPN1、GABRA1、ESR2、AR、HSP90-1、PRSS1这12个基因靶点是逍遥散和柴胡疏肝散共同抗抑郁的潜在靶点；GLUL、CREB1、GAD1、SLC6A1、GAD2、DAO、ADCY5、PPP1R1B、CRHR1、SLC1A2是逍遥散特有抗抑郁靶点；ALB是柴胡疏肝散特有抗抑郁靶点。综上所述，逍遥散和柴胡疏肝散既可以通过两药共有靶点治疗抑郁症，也可通过特有靶点达到抗抑郁的效果。如此一来，两者“同病异治”抑郁症的作用机制有了进一步的探索，为今后抗抑郁症的治疗提供理论基础，为研发抗抑郁新药提供新思路。</p></sec><sec id="s9"><title>基金项目</title><p>成都中医药大学科技发展基金(ZRQN2020001)；四川省青年科技创新团队项目(19CXTD0055)。</p></sec><sec id="s10"><title>文章引用</title><p>刘文雯,木本荣,钟 馨,黄志航,刘文萱,卢长青,梁小清,王冬梅,国锦琳. 基于网络药理学和生物信息学探索逍遥散和柴胡疏肝散“同病异治”抑郁症的作用机制Study on Mechanism of Xiaoyao Powder and Chaihu Shugan Powder for Treating Depression in “the Same Disease with Different Treatments” Based on Network Pharmacology and Bioinformatics[J]. 中医学, 2021, 10(02): 200-215. https://doi.org/10.12677/TCM.2021.102028</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40938-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">赵映霞, 许腾, 田俊生, 秦雪梅. 柴归颗粒对慢性不可预知温和刺激抑郁大鼠模型肠道菌群的作用[J]. 中草药, 2021, 52(3): 736-743.</mixed-citation></ref><ref id="hanspub.40938-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Gong, H.F., Xu, H.M., et al. (2019) Abnormal Voxel-Wise Degree Centrality in Patients with Late-Life Depression: A Resting-State Functional Magnetic Resonance Imaging Study. Frontiers in Psychiatry, 10, 1024.  
&lt;br&gt;https://doi.org/10.3389/fpsyt.2019.01024</mixed-citation></ref><ref id="hanspub.40938-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">初倩, 阎兆君, 黄巧艺. 巴戟天-苍术药对治疗青少年抑郁症的网络药理学研究[J]. 湖南中医药大学学报, 2020, 40(11): 1371-1378.</mixed-citation></ref><ref id="hanspub.40938-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">许鹏, 章程鹏, 周童. 中医药改善抑郁症发病机制的研究进展[J/OL]. 中国实验方剂学杂志, 1-7.</mixed-citation></ref><ref id="hanspub.40938-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">童伟隆, 吴景竹, 赵桂琴, 赵明勇. 柴胡疏肝散加减配合针灸对抑郁症疗效及相关指标的影响[J]. 中华中医药学刊, 2019, 37(1): 227-229.</mixed-citation></ref><ref id="hanspub.40938-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">毛梦迪, 尚立芝, 许二平. 半夏厚朴汤治疗抑郁症研究进展[J]. 中国实验方剂学杂志, 2020, 26(23): 37-43.</mixed-citation></ref><ref id="hanspub.40938-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">张煜萱, 崔博, 邹之璐, 任荔, 陈刚. 越鞠丸治疗气郁体质抑郁症患者及改善血清BDNF水平的临床对照研究[J]. 辽宁中医杂志, 2018, 45(5): 960-963.</mixed-citation></ref><ref id="hanspub.40938-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">高耀, 穆俊芳, 令狐婷, 周玉枝, 高晓霞, 田俊生, 秦雪梅. 逍遥散治疗抑郁症代谢网络的模块划分与生物学机制研究[J/OL]. 药学学报, 1-19. http://kns.cnki.net/kcms/detail/11.2163.R.20201117.0956.009.html</mixed-citation></ref><ref id="hanspub.40938-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">吴源陶, 邹译娴, 王理槐. 运用网络药理学探讨开心散治疗抑郁症的作用机制[J]. 湖南中医药大学学报, 2020, 40(4): 445-451.</mixed-citation></ref><ref id="hanspub.40938-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">李君玲, 夏恺, 王田, 薛晓兴, 阎晶露, 赵慧辉, 马雪玲, 李玉波, 王伟. 四逆散治疗抑郁症研究进展[J]. 环球中医药, 2017, 10(1): 110-113.</mixed-citation></ref><ref id="hanspub.40938-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">安继东, 郭旭彤, 陈分乔, 梅建强. 近5年中药治疗抑郁症及其作用机制研究进展[J]. 辽宁中医药大学学报, 2020, 22(8): 139-142.</mixed-citation></ref><ref id="hanspub.40938-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">丁涛, 张阳, 纵横. 从《伤寒论》太阳篇浅探张仲景“同病异治“与“异病同治”思想[J]. 中医药临床杂志, 2016, 18(10): 1415-1417.</mixed-citation></ref><ref id="hanspub.40938-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Luo, T.T., Lu, Y., Yan, S.K., et al. (2020) Network Pharmacology in Research of Chinese Medicine for Mula: Methodology, Application and Prospective. Chinese Journal of Integrative Medicine, 26, 72-80.  
&lt;br&gt;https://doi.org/10.1007/s11655-019-3064-0</mixed-citation></ref><ref id="hanspub.40938-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">李昊楠, 孔浩天, 史永平, 等. 基于网络药理学的双丹方治疗冠心病的作用机制研究[J]. 中草药, 2019, 50(20): 4985-4994.</mixed-citation></ref><ref id="hanspub.40938-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Li, H.N., Kong, H.T., Shi, Y.P., et al. (2019) Mechanism of Shuangdan Recipe on Treatment of Coronary Heart Disease Based on Network Pharmacology. Chinese Traditional and Herbal Drugs, 50, 4985-4994.</mixed-citation></ref><ref id="hanspub.40938-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">王俊, 郭丽, 吴建盛, 汤丽华, 胡栋. 大数据背景下的生物信息学研究现状[J]. 南京邮电大学学报(自然科学版), 2017, 37(4): 62-67.</mixed-citation></ref><ref id="hanspub.40938-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J.X., Zhong, J.C., Chen, G., Li, M., Wu, F.X. and Pan, Y. (2015) ClusterViz: A Cytoscape APP for Cluster Analysis of Biological Network. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 12, 815-822.  
&lt;br&gt;https://doi.org/10.1109/TCBB.2014.2361348</mixed-citation></ref><ref id="hanspub.40938-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">黄志航, 刘文雯, 钟馨, 木本荣, 王冬梅, 国锦琳. 探析越鞠丸和柴胡疏肝散“同病异治”抑郁症的作用机制[J]. 中医学, 2021, 10(1): 1-13.</mixed-citation></ref><ref id="hanspub.40938-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">高耀, 吴丹, 田俊生, 周玉枝, 高晓霞, 秦雪梅. 逍遥散和开心散“同病异治”抑郁症的网络药理学作用机制研究[J]. 中草药, 2018, 49(15): 3483-3492.</mixed-citation></ref><ref id="hanspub.40938-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tsao, C.W., Lin, Y.S., Chen, C.C., et al. (2006) Cytokines and Serotonin Transporter in Patients with Major Depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30, 899-905.  
&lt;br&gt;https://doi.org/10.1016/j.pnpbp.2006.01.029</mixed-citation></ref><ref id="hanspub.40938-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">林映仙, 杨文静, 曹宁宁, 赵利斌, 裴帅, 陈宇洲, 肖学凤. 逍遥散及其加减方的抗抑郁作用比较研究[J]. 中草药, 2021, 52(1): 137-144.</mixed-citation></ref><ref id="hanspub.40938-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Man, C.F., Li, C., Gong, D.D., et al. (2014) Meta-Analysis of Chinese Herbal Xiaoyao Formula as an Adjuvant Treatment in Relieving Depression in Chinese Patients. Complementary Therapies in Medicine, 22, 362-370.  
&lt;br&gt;https://doi.org/10.1016/j.ctim.2014.02.001</mixed-citation></ref><ref id="hanspub.40938-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">宫文霞, 周玉枝, 李肖, 等. 当归抗抑郁化学成分及药理作用研究进展[J]. 中草药, 2016, 47(21): 3905-3911.</mixed-citation></ref><ref id="hanspub.40938-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Andrews, P.W., Bharwani, A., Lee, K.R., et al. (2015) Is Serotonin an Upper or a Downer? The Evolution of the Serotonergic System and Its Role in Depression and the Antidepressant Response. Neuroscience &amp; Biobehavioral Reviews, 51, 164. &lt;br&gt;https://doi.org/10.1016/j.neubiorev.2015.01.018</mixed-citation></ref><ref id="hanspub.40938-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">熊庭旺, 吴芹, 刘杰, 等. 基于神经递质途径抗焦虑中药及其复方研究进展[J]. 中国中药杂志, 2020, 45(1): 14.</mixed-citation></ref><ref id="hanspub.40938-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">丛梦雨, 梁晓霞, 陈丰连, 曹骋, 王术玲. 疏肝理脾类方调控色氨酸代谢的抗抑郁作用机制及共性药效物质[J/OL]. 中国中药杂志, 1-13.</mixed-citation></ref><ref id="hanspub.40938-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">张素勤, 刘宝山, 郎娜, 等. 滋肾疏肝宁心方联合针灸治疗更年期抑郁症临床疗效及对患者血清雌激素和子宫内膜厚度的影响[J]. 四川中医, 2018, 36(2): 157-160.</mixed-citation></ref><ref id="hanspub.40938-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">林木海. 吸收成分橙皮苷发挥类似枳壳厚朴抗抑郁及促胃肠动力作用及分子机制研究[D]: [硕士学位论文]. 厦门: 厦门大学, 2018.</mixed-citation></ref><ref id="hanspub.40938-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">袁铭, 刘向慧, 张静晓, 胡晓盈. 白芍成分治疗抑郁症的网络药理学研究[J]. 生物化工, 2020, 6(6): 20-24+32.</mixed-citation></ref><ref id="hanspub.40938-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Nie, H., Deng, Y.J., Zheng, C.Y., et al. (2020) A Network Pharmacology-Based Approach to Explore the Effects of Chaihu Shugan Powder on a Non-Alcoholic Fatty Liver Rat Model through Nuclear Receptors. Journal of Cellular and Molecular Medicine, 24, 5168-5184. &lt;br&gt;https://doi.org/10.1111/jcmm.15166</mixed-citation></ref><ref id="hanspub.40938-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y.-Y., Hu, D., Fan, Q.-Q., et al. (2019) Study on Mechanism of Chaihu Shugan Powder for Treating Depression Based on Network Pharmacology. Chinese Journal of Integrative Medicine, 26, 921-928.</mixed-citation></ref><ref id="hanspub.40938-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Taciak, P.P., Lysenko, N. and Mazurek, A.P. (2018) Drugs Which Influence Serotonin Transporter and Serotonergic Receptors: Pharmacological and Clinical Properties in the Treatment of Depression. Pharmacological Reports, 70, 37-46.  
&lt;br&gt;https://doi.org/10.1016/j.pharep.2017.07.011</mixed-citation></ref><ref id="hanspub.40938-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Uchida, S., Yamagata, H., Seki, T. and Watanabe, Y. (2018) Epigenetic Mechanisms of Major Depression: Targeting Neuronal Plasticity. Psychiatry and Clinical Neurosciences, 72, 212-227. &lt;br&gt;https://doi.org/10.1111/pcn.12621</mixed-citation></ref><ref id="hanspub.40938-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Dean, J. and Keshavan, M. (2017) The Neurobiology of Depression: An Integrated View. Asian Journal of Psychiatry, 27, 101-111. &lt;br&gt;https://doi.org/10.1016/j.ajp.2017.01.025</mixed-citation></ref><ref id="hanspub.40938-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">徐静, 史九波, 张凤岐, 程治军, 史玲玲, 李艳平, 申杰. 血清C-反应蛋白、白蛋白、前白蛋白、肿瘤坏死因子-α水平与抑郁症患者HAMD评分的关系[J]. 国际精神病学杂志, 2020, 47(4): 682-685.</mixed-citation></ref></ref-list></back></article>